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Abstract
Background: The smoothelin-like 1 protein (SMTNL1) can associate with tropomyosin (Tpm) and calmodulin (CaM),
two proteins essential to the smooth muscle contractile process. SMTNL1 is phosphorylated at Ser301 by protein
kinase A during calcium desensitization in smooth muscle, yet the effect of SMTNL1 phosphorylation on Tpm- and
CaM-binding has yet to be investigated.
Results: Using pull down studies with Tpm-Sepharose and CaM-Sepharose, we examined the interplay between
Tpm binding, CaM binding, phosphorylation of SMTNL1 and calcium concentration. Phosphorylation greatly
enhanced the ability of SMTNL1 to associate with Tpm in vitro; surface plasmon resonance yielded a 10-fold
enhancement in KD value with phosphorylation. The effect on CaM binding is more complex and varies with the
availability of calcium.
Conclusions: Combining both CaM and Tpm with SMTNL1 shows that the binding to both is mutually exclusive.
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Background
Smoothelin-like 1 protein (SMTNL1), also termed calponin
homology-associated with smooth muscle (CHASM) pro-
tein, was originally identified as a protein phosphorylated in
response to cyclic nucleotide-dependent protein kinase (i.e.,
protein kinase A (PKA) and protein kinase G (PKG)) acti-
vation during calcium desensitization of gastrointestinal
smooth muscle [1]. Additional studies have revealed a role
for SMTNL1 in vascular smooth muscle contractile activity,
as well as cardiovascular and skeletal muscle adaptation to
exercise, development and pregnancy [2–6].
The ubiquitous calmodulin (CaM) is the primary cellular
signal transducer that provides spatial and temporal re-
sponses to changes in intracellular calcium levels [7]. CaM
provides signaling by association with specific binding sites
in target proteins, both in its calcium-saturated (Ca-CaM)
or its calcium-free (apo-CaM) form [8, 9]. We have previ-
ously reported that SMTNL1 possesses two CaM-binding
sites: a classic CaM-binding domain (CBD1, amino acids
310–325) in the center of the protein as well as an IQ-
motif that serves as an apo-CaM-binding site (CDB2,
amino acids 439–457) located in the carboxy-terminal
calponin homology domain [10–12]. SMTNL1 was estab-
lished as a bona fide CaM-binding protein within aortic
A7r5 smooth muscle cells using the proximity ligation
assay. In this regard, CBD1 is thought to provide the major-
ity of CaM-binding in situ; however, CBD2 may contribute
cooperatively to binding [12].
A second binding partner of SMTNL1 has also been
identified in smooth muscle. Tropomyosin (Tpm), a
muscle protein that aids in the stabilization of actin fila-
ments, is incorporated as super-helical polymers along
smooth muscle thin filaments and contribute to the
regulation of actin-myosin cross bridge cycling during
smooth muscle contraction [13–15]. In smooth muscle,
two Tpm isoforms (Tpm1.4 and Tpm2.1; previously
identified as Tmsm-α/Tm6 and Tmsm-β/Tm1β, respect-
ively [16]) are predominantly expressed [17]. SMTNL1
was shown to associate with smooth muscle Tpm α/β di-
mers with a binding surface comprising of its N-terminal
intrinsically-disordered region and the C-terminal calponin
homology domain [18].
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Previous in vitro studies have defined SMTNL1 as a
Tpm- and CaM-binding protein [10–12, 18, 19]. More-
over, the phosphorylation of SMTNL1 was identified
during calcium desensitization of smooth muscle [1, 5].
However, the effect of phosphorylation on the ability of
SMTNL1 to associate with Tpm and/or CaM has not
been investigated. Intriguingly, the binding domains for
CaM (CBD1 and CBD2) are localized in close vicinity to
the Tpm-binding surface on the SMTNL1 protein. In
addition, the Ser301 phosphorylation site targeted by
cyclic nucleotide-dependent protein kinases (i.e., PKA
and PKG) is located near CBD1 and within the Tpm-
binding region [11, 18]. This led us to inquire about the
interplay of SMTNL1 phosphorylation and calcium
levels on the multi-functionality of Tpm- and CaM-
binding. Herein, we demonstrate that phosphorylation of
Ser301 greatly enhanced the ability of SMTNL1 to asso-
ciate with smooth muscle Tpm in vitro. The effect of
Ser301 phosphorylation on CaM binding was more
complex and varied with the availability of calcium.
Combining both CaM and Tpm revealed that binding
with SMTNL1 was mutually exclusive.
Methods
Materials
PreScission Protease, glutathione-Sepharose and CNBr-
activated Sepharose were from GE Healthcare (Piscataway,
NJ). The Phos-tag acrylamide reagent was from NARD
Chemicals (Kobe City, Japan). Smooth muscle Tpm was
a purified α/β heterodimer of chicken gizzard
Tpm1.4sm(a.a.b.d) (equivalent to Tm6 or Tmsm-α) and
Tpm2.1sm(a.b.a.d) (equivalent to TM-1, βTm or Tmsm-β)
[16] and was provided by Dr. Michael Walsh (Univer-
sity of Calgary). CaM was provided by Dr. Hans Vogel
(University of Calgary). PKA was purified from bovine
heart using the method described in [20].
Expression and Purification of SMTNL1
A clone comprising the Tpm-binding region of SMTNL1
(SMTNL1-TMB, amino acids 195–459; NP_077192) was
described previously [18, 19]. SMTNL1-TMB was
expressed as a glutathione S-transferase (GST)-fusion
protein in E. coli and purified with glutathione-
Sepharose. The fusion protein was cleaved with PreScis-
sion Protease, and GST was removed by an additional
pass over glutathione-Sepharose along with a final clean-
up using MonoQ anion exchange chromatography. In
some cases, SMTNL1-TMB was phosphorylated with
PKA at a molar ratio of 500:1 (SMTNL1: PKA) in a buf-
fer consisting of 2 mM MgCl2, 0.2 mM ATP, 25 mM
HEPES and 150 mM NaCl. The phosphorylated protein
was buffer-exchanged and concentrated using a 3 kDa cut-
off centrifugation filter unit (EMD Millipore, Billerica, MA).
Tpm-Sepharose binding assay
Purified smooth muscle Tpm or Tris-HCl (as control) was
covalently bound to CNBr-activated Sepharose following the
manufacturers’ instructions and as described in [19].
SMTNL1-TMB (200 μg) was incubated with 40 μL of Tpm-
Sepharose or Control-Sepharose in binding buffer (20 mM
Tris-HCl, pH 7.5 with 0.1% (v/v) β-mercaptoethanol) for 2 h
at 4 °C and then washed extensively with the same buffer
supplemented with 150 mM NaCl. Bound protein was
eluted with SDS-PAGE loading buffer, separated by gel elec-
trophoresis, and detected by Coomassie stain.
Calmodulin-Sepharose binding assay
Calmodulin (CaM)-Sepharose pull-down experiments were
completed as described previously [11]. Briefly, SMTNL1-
TMB (200 μg) was incubated with 40 μL of CaM-Sepharose
in binding buffer (20 mM HEPES, pH 7.0 in the presence of
5 mM CaCl2 (Ca-CaM) or 1 mM EDTA (apo-CaM)). After
incubation for 1 h at 4 °C, the CaM-Sepharose was washed
extensively with the same buffer supplemented with
150 mM NaCl. Bound SMTNL1-TMB protein was eluted
with SDS-PAGE loading buffer, separated by gel electro-
phoresis, and detected by Coomassie stain. In some experi-
ments, SMTNL1-TMB was premixed with Tpm in different
molar ratios, allowed to form complexes for 1 h at 4 °C and
then added to the CaM-Sepharose.
Surface Plasmon Resonance (SPR)
The binding between Tpm and SMTNL1-TMB with or
without phosphorylation was evaluated by SPR using a
BIAcore X100 instrument (GE Healthcare). Purified
Tpm was immobilized via amine-coupling onto a CM5
sensor chip (GE Healthcare). The running buffer con-
tained 20 mM HEPES pH 7.5, 100 mM KCl, 1 mM
DTT, and 0.005% (v/v) Tween-20. Five concentrations of
SMTNL1-TMB from 0.12 to 10 μM were prepared by
serial dilution and were injected at a flow rate of 30 μL/
min with a contact time of 1 min at 25 °C. The chip was
regenerated by injecting 1 M NaCl for 4 min followed
by glycine-HCl (10 mM, pH 3.0) for 1 min. Each experi-
ment was repeated three times (n = 3) to obtain a stand-
ard error (SE). The BIAevaluation software 2.0 (GE
Healthcare) was used to analyze the SPR sensorgrams
and to obtain the dissociation constants (Kd).
Data analysis
Values are presented as the mean ± S.E.M., with n indicating
the number of independent experiments. Data were ana-
lyzed with two-tailed Student’s t test, or for comparison of
multiple groups, with one-way analysis of variance
(ANOVA) and Tukey’s post hoc test. Differences were con-
sidered to be statistically significant for p < 0.05. All statis-
tical analyses were performed using the GraphPad Prism 6.0
program.
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Results
Phosphorylation of SMTNL1 by PKA enhances
Tpm-binding potential
Full-length SMTNL1 protein exhibits reduced stability that
complicates conclusions from in vitro binding experiments.
A truncated form of SMTNL1 (i.e., SMTNL1-TMB) was
used since this clone is stable under the conditions and
times used; furthermore, SMTNL1-TMB contains all known
functional elements of SMTNL1 (e.g., CBD1, CBD2,
calponin-homology (CH) domain, Tpm-binding regions and
Ser301 phosphorylation site; Fig. 1a). SMTNL1-TMB could
be effectively phosphorylated with PKA; the phosphorylation
stoichiometry was assessed with Phos-tag SDS-PAGE and
judged to be complete (i.e., ~ 1 mol phosphate/mol
SMTNL1) after 16 h incubation at 4 °C (Fig. 1b). The bind-
ing of SMTNL1-TMB to Tpm was examined in pull-down
assays with purified smooth muscle Tpm (mixture of
Tpm1.4 and Tpm2.1 isoforms) immobilized to Sepharose
resin (Tpm-Sepharose). SMTNL1-TMB was recovered from
Tpm-Sepharose while no interaction with Control-
Sepharose was observed (Fig. 1c). Some Tpm could be re-
leased from the Sepharose column with application of SDS
elution buffer and boiling. This was anticipated given that
smooth muscle Tpm exists as coiled-coil heterodimers [21],
and it was unlikely that all Tpm molecules could be cova-
lently coupled to the CNBr-Sepharose resin. Approximately
2-fold more phosphorylated SMTNL1-TMB could be recov-
ered from pull-down assays with Tpm-Sepharose (Fig. 1d)
when compared with unphosphorylated SMTNL1-TMB.
Binding constants for a kinetic series, 0–10 μM phosphor-
ylated SMTNL1-TMB provided a KD of 3.2 × 10
−7M with
biophysical analyses by SPR (Additional file 1: Figure S1),
a response that was enhanced 10-fold when compared
to unphosphorylated SMTNL1-TMB (3.0 × 10−6M).
The SPR assays provided a similar KD for unpho-
sphorylated SMTNL1 and Tpm as previously defined
by isothermal titration calorimetry (ITC) assays [19].
We previously reported that the SMTNL1 binding
surface for Tpm included a central portion of the
intrinsically-disordered region, located proximal to the
Ser301 phosphorylation site, as well as a surface of
the calponin homology (CH) domain located at the
C-terminus [18]. So, it is not unexpected that phos-
phorylation at Ser301 could alter the electrostatic
properties and/or the intramolecular conformation of
the Tpm-binding surface on SMTNL1.
Phosphorylation of SMTNL1-TMB influences binding to
CaM-Sepharose
The Ser301 phosphorylation site of SMTNL1 is located
in close proximity to the Ca-CaM binding domain
(CBD1, amino acids 310–325 [11]). It was expected that
the phosphorylation of SMTNL1-TMB by PKA would
impact the association with Ca-CaM and not with apo-
CaM, since the binding of the latter was linked to an
IQ-domain at the C-terminus (CBD2, amino acids 439–
457 [10]). Indeed, we observed reductions in Ca-CaM-
Sepharose binding for phosphorylated SMTNL1-TMB,
with recovery of approximately 30% less bound material
(Fig. 2a). Surprisingly, the phosphorylation of SMTNL1-
TMB protein also impacted upon binding to apo-CaM-
Sepharose (Fig. 2b). Although a general reduction in
SMTNL1-TMB bound to CaM was observed in the apo
condition (i.e., ~60% less SMTNL1-TMB recovered on
the resin), the recovery of phosphorylated SMTNL1-
TMB from the resin was further reduced to approxi-
mately 20% of the unphosphorylated material (Fig. 2b).
We have previously demonstrated that the binding of
SMTNL1-TMB to CaM was influenced by calcium, with
SMTNL1 binding to CaM-Sepharose decreased by ap-
proximately 50% in the apo-calcium condition [11].
Phosphorylation and calcium influence SMTNL1-TMB
binding to CaM-Sepharose in the presence of Tpm
Equimolar amounts of SMTNL1-TMB and Tpm pro-
teins were pre-incubated and then applied to CaM-
Sepharose so that competition between CaM and Tpm
for binding to SMTNL1-TMB could be assessed. Binding
of SMTNL1-TMB to apo-CaM-Sepharose was reduced
by approximately 60% by the addition of Tpm to
SMTNL1-TMB prior to capture with the resin (Fig. 2b).
These data indicate that Tpm could interfere with the
apo-CaM binding properties of SMTNL1-TMB, likely
due to the proximity of the two binding sites within the
calponin homology (CH) domain. Furthermore, we can
conclude that SMTNL1-TMB interacts with Tpm more
strongly than with apo-CaM. This was not unexpected
as the interaction of SMTNL1 with apo-CaM is weak
(Kd ~10−6 M [10]). The results of the binding assays
were not affected by the order of addition of proteins
since pre-incubating SMTNL1-TMB with CaM-
Sepharose followed by competition with Tpm showed
the same reduction in binding (data not shown). The
subsequent addition of Tpm to the mixture of phosphor-
ylated SMTNL1 and apo-CaM-Sepharose, shown in
Fig. 2b, further decreased binding potential to barely
detectably levels. When investigating interactions with
Ca-CaM, the binding of unphosphorylated SMTNL1-
TMB to Ca-CaM-Sepharose was not significantly influ-
enced by the addition of equimolar amounts of Tpm
(Fig. 2a). However, the addition of Tpm did significantly
reduce the recovery of phosphorylated SMTNL-TMB on
the Ca-CaM-Sepharose resin.
SMTNL1 phosphorylation diminishes Ca-CaM-binding
potential under conditions of high Tpm content
The intracellular Tpm concentration is predicted to be
significantly higher than that of SMTNL1, as judged
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from the relative staining intensities of 2D-SDS-PAGE
gels [1]. So, the incubation of SMTNL1-TMB with dif-
ferent molar ratios of Tpm prior to the addition of
CaM-Sepharose was used to reveal additional informa-
tion about the character of the protein complex forma-
tion. Increasing the amounts of Tpm resulted in a
notable decrease in the binding of SMTNL1-TMB to
apo-CaM-Sepharose (Fig. 3a). Moreover, there was min-
imal influence of increased Tpm on the binding of phos-
phorylated SMTNL1-TMB in the apo-CaM condition
(Fig. 3b). The small inhibitory effect of increasing Tpm
concentration on the amount of SMTNL1-TMB retained
on Ca-CaM Sepharose suggests a greater affinity of
SMTNL1-TMB for Ca-CaM over Tpm (Fig. 3c). How-
ever, distinct effects were observed for Ca-CaM binding
of phosphorylated SMTNL1-TMB under conditions of
high Tpm (Fig. 3d). In this case, the phosphorylation of
SMTNL1-TMB suppressed Ca-CaM binding potential in
favour of Tpm.
Discussion
Phosphorylation events are known to regulate binding of
CaM to target proteins. Several examples of phosphorylation
within or near CaM-binding domains (CBDs) have been
reported in the literature, including but not limited to
smooth muscle myosin light chain kinase [22], MARKS
protein [23], plasma membrane Ca2+-ATPase [24],
endothelial nitric oxide synthase (eNOS) [25], and the
Ca2+-dependent K+-channel [26]. CaM binds to its tar-
gets by wrapping around a short amphipathic helix
within the CBD [8, 9], thus the phosphorylation of resi-
dues within a CBD can disrupt CaM interactions even
if the Ser/Thr residues subject to phosphorylation are
Fig. 1 The phosphorylation of SMTNL1 by PKA alters its
tropomyosin-binding potential. a The SMTNL1 protein contains: a
C-terminal calponin homology (CH) domain, Ser301 PKA-
phosphorylation site, Ca-calmodulin (CaM)-binding domain (CBD1),
apo-CaM-binding domain (CBD2), and tropomyosin (Tpm)-binding
domain (indicated as the hatched area). b Purified recombinant
SMTNL1-TMB was incubated with PKA as described in the Methods
section. Samples were withdrawn at the indicated times and subjected
to Phos-tag SDS-PAGE; two discrete bands representing unphosphory-
lated SMTNL1-TMB (0P, TMB) or SMTNL1-TMB phosphorylated at
Ser301 (1P, pTMB) were detected by Coomassie stain. Samples
subjected to Phos-tag SDS-PAGE in the absence of MnCl2 confirmed
the shift in band migration to be a result of phosphorylation.
c Unphosphorylated or phosphorylated SMTNL1-TMB (200 μg) was
incubated with 40 μL of Tpm-Sepharose (α/β-heterodimer:
Tpm1.4/Tpm2.1). Bound SMTNL1-TMB was eluted with boiling 0.1%
SDS solution and detected with Coomassie staining of SDS-PAGE
gels. d The SMTNL1-TMB bands were quantified by densitometry,
and binding to Tpm-Sepharose was expressed as percentage of
the SMTNL1-TMB binding found for the unphosphorylated state.
All experiments are n = 3–5 and were analyzed by Student’s t-test.
*- Significantly different from unphosphorylated
SMTNL1-TMB, p < 0.05
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not necessarily required for CaM binding [22]. Herein,
we describe a novel incidence where phosphorylation
regulates CaM binding to a target protein. In this case,
the PKA-dependent phosphorylation of SMTNL1 at
Ser301 modulates both Ca- and apo-CaM binding.
Ser301 lies well upstream of the core hydrophobic resi-
dues within CBD1 required for Ca-CaM-binding (i.e.,
20 amino acids from Phe321 which is the critical con-
tributor [11]). It is likely that the distance between
Ser301 and the hydrophobic patch of CBD1 is too dis-
tant for phosphorylation to directly block Ca-CaM
docking. This agrees with our observation that the rate
of PKA-dependent phosphorylation at Ser301 was not
influenced when apo- or Ca-CaM was included in the
kinase assay (unpublished results). We have previously
demonstrated that intramolecular interactions between
the C-terminal IQ motif (localization of the apo-CaM
binding site, CBD2) and the intrinsically disordered region
(localization of the phosphorylation site) influence apo-
CaM binding [11, 12]. Furthermore, a portion of the N-
terminal intrinsically disordered region forms intramo-
lecular contacts with the globular C-terminal calponin
homology (CH) domain [18]. Thus, it is conceivable that
phosphorylation within the N-terminal region has far-
reaching effects in the C-terminal domain and can attenu-
ate both Ca- and apo-CaM binding potentials.
The phosphorylation of SMTNL1-TMB enhanced the
Tpm-binding potential in both pull down studies and by
confirming SPR assays. Inconsequential amounts of non-
specific Tpm-binding were found with CaM-Sepharose,
and its binding was not influenced by the presence of
SMTNL1-TMB, irrespective of phosphorylation or cal-
cium. Thus, we conclude that a heterotrimeric complex
of SMTNL1-TMB, CaM and Tpm was not formed under
any of the binding conditions employed. Since no
heterotrimer was generated, we suggest that Tpm and
Ca-CaM compete for a similar binding site on
SMTNL1-TMB. This conclusion is further supported by
the fact that the binding surfaces for CaM and Tpm
overlap on SMTNL1. Indeed, only very weak binding of
Tpm is observed with the isolated CH domain (contain-
ing: CBD2; apo-CaM binding) in the absence of the
intrinsically-disordered upstream sequence (containing:
CBD1, Ca-CaM binding; and Ser301, phosphorylation
consensus sequence) [18].
Our findings place SMTNL1 in a position to influence
both Ca2+/CaM-regulated contractile events and Ca2+
desensitization pathways in smooth muscle. Depending
on intracellular calcium concentration and cyclic
nucleotide-dependent kinase activation, SMTNL1 is pre-
dicted to cycle between Tpm-bound and Ca-CaM-
bound complexes. The impact of SMTNL1 on smooth
muscle contractile processes may be via its binding part-
ners and associations with the contractile filament. In its
dephosphorylated state SMTNL1 has weaker affinity for
Tpm and would be more likely to associate with CaM.
With an increase in intracellular calcium due to a con-
tractile signal, Ca-CaM could bind to SMTNL1 and ini-
tiate the dissociation of the complex from the thin
filament. Unphosphorylated SMTNL1 can inhibit my-
osin light chain phosphatase (MLCP) activity in vitro
[27], so the release of SMTNL1 could attenuate MLCP-
dependent dephosphorylation of myosin regulatory light
chain (LC20). Conversely, SMTNL1 phosphorylation dur-
ing calcium desensitization of smooth muscle could provide
enhanced binding to Tpm and restrict binding of CaM in
the apo-state, securing phosphorylated SMTNL1 with Tpm
on the thin filament. The weak binding modes of SMTNL1
with apo-CaM might not possess enough stability to occur
in vivo [12]. While the physiological significance of
Fig. 2 Interdependency of SMTNL1 phosphorylation, calcium and tropomyosin on calmodulin-binding. SMTNL1-TMB (200 μg, 7 nmol) was
incubated with an equimolar amount of Tpm. The mixture was then incubated with CaM-Sepharose (40 μL; ligand density of ~10–14 μmol/
mL) in the presence (a; Ca-CaM, 5 mM CaCl2) or absence (b; apo-CaM, 1 mM EDTA) of calcium. Some experiments were completed with
SMTNL1-TMB that had been previously phosphorylated with PKA. After washing, the retention of SMTNL1-TMB or phosphorylated SMTNL1-
TMB was analyzed. The band densities were quantified and binding to CaM-Sepharose expressed as percentage of SMTNL1-TMB recovered
under maximal binding conditions (i.e., Ca-CaM in the absence of Tpm). All experiments are n = 3–5 and were analyzed by one-way ANOVA with
Tukey’s post hoc analysis. Different letters indicate significant differences among groups (a,b,c: comparison among all Ca-CaM conditions; d,e,f: compari-
son among all apo-CaM conditions; p < 0.05)
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SMTNL1 association with the contractile filament in situ
has not been investigated, we speculate that the protein
may act in analogous manners to caldesmon or calponin
on actin-myosin cross bridge cycling. Calponin interacts
with many cytoskeleton and related proteins (including
tropomyosin) and functions as an inhibitor of actin-
activated myosin ATPase [28]. The binding of Ca-CaM dis-
sociates calponin from the actin filament to facilitate
smooth muscle contraction [29]. Calponin can also be
phosphorylated in response to cyclic nucleotide signals to
cause a reduced affinity for the thin filament [30]. Caldes-
mon is another actin filament-associated regulatory protein;
it also binds to Tpm and regulates cross-bridge cycling in a
Ca-CaM dependent manner [31]. A detailed physiological
analysis of the CaM- and Tpm-interactions of SMTNL1
and their functional implications are required to provide a
clear description of role of SMTNL1 in smooth muscle
contractility. Further investigation will be needed to verify
the role of SMTNL1 in fine-tuning thin filament dynamics.
Conclusions
Herein, we provide evidence that calcium availability in-
creases CaM association with SMTNL1, and CaM and
tropomyosin binding to SMTNL1 are mutually exclusive
events. Moreover, SMTNL1 binding to CaM is reduced by
phosphorylation of Ser301 while binding to tropomyosin is
enhanced. We propose a model whereby SMTNL1 can
exist in distinct complexes with either Tpm or CaM, de-
pending on availability of calcium and activity of PKA. This
Fig. 3 SMTNL1 phosphorylation precludes Ca-CaM-binding in favour of Tpm-binding under conditions of high Tpm content. SMTNL1-TMB or
phosphorylated SMTNL1-TMB (concentrations as described in Fig. 2) was pre-incubated with the indicated molar ratio of purified α/β Tpm dimer.
The mixtures were then added to CaM-Sepharose in the absence (a, c; apo-CaM, 1 mM EDTA), or presence (b, d; Ca-CaM, 5 mM CaCl2) of calcium.
After extensive washing, bound SMTNL1-TMB was eluted and detected with Coomassie staining of SDS-PAGE gels. The band density was quantified
and binding expressed as percentage of maximum binding within each condition. All experiments are n = 3 and were analyzed by one-way ANOVA
with Tukey’s post hoc analysis. Different letters indicate significant differences among groups (p < 0.05)
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switching mechanism could aid in the fine-tuning of
smooth muscle contraction.
Additional file
Additional file 1: Figure S1. SPR measurements for binding of
SMTNL1-TMB to tropomyosin. Sensorgrams and data fittings are provided
for unphosphorylated and phosphorylated (S301 with PKA) SMTNL1-TMB
protein with tropomyosin immobilized via amine-coupling to a CM5
sensor chip. (DOCX 714 kb)
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